AnaptysBio, Inc. $ANAB Shares Sold by Voya Investment Management LLC

by · The Markets Daily

Voya Investment Management LLC cut its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 82.2% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 12,961 shares of the biotechnology company’s stock after selling 60,044 shares during the period. Voya Investment Management LLC’s holdings in AnaptysBio were worth $397,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ANAB. HighMark Wealth Management LLC boosted its stake in shares of AnaptysBio by 58.2% in the second quarter. HighMark Wealth Management LLC now owns 145,550 shares of the biotechnology company’s stock valued at $3,231,000 after purchasing an additional 53,550 shares during the period. Panagora Asset Management Inc. acquired a new position in AnaptysBio in the 2nd quarter worth $741,000. Allianz Asset Management GmbH acquired a new position in AnaptysBio in the 2nd quarter worth $337,000. Los Angeles Capital Management LLC purchased a new position in AnaptysBio in the 2nd quarter valued at about $334,000. Finally, Granahan Investment Management LLC grew its stake in shares of AnaptysBio by 38.1% during the first quarter. Granahan Investment Management LLC now owns 146,491 shares of the biotechnology company’s stock valued at $2,723,000 after acquiring an additional 40,412 shares in the last quarter.

Insiders Place Their Bets

In other news, CFO Dennis Mulroy sold 10,000 shares of the firm’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $50.00, for a total value of $500,000.00. Following the sale, the chief financial officer owned 9,401 shares in the company, valued at approximately $470,050. This trade represents a 51.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director J. Anthony Ware sold 3,900 shares of the business’s stock in a transaction dated Tuesday, December 23rd. The shares were sold at an average price of $49.58, for a total value of $193,362.00. Following the transaction, the director owned 9,630 shares in the company, valued at $477,455.40. This represents a 28.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 63,766 shares of company stock worth $3,011,004 in the last 90 days. 33.50% of the stock is owned by company insiders.

AnaptysBio Stock Down 7.3%

ANAB opened at $44.95 on Friday. AnaptysBio, Inc. has a 12-month low of $12.21 and a 12-month high of $52.47. The firm has a market capitalization of $1.24 billion, a P/E ratio of -15.94 and a beta of 0.32. The stock has a fifty day moving average of $41.83 and a 200-day moving average of $30.78.

AnaptysBio (NASDAQ:ANAB – Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $1.58. The business had revenue of $76.32 million for the quarter, compared to the consensus estimate of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. On average, analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio announced that its board has authorized a share buyback plan on Friday, November 21st that allows the company to repurchase $100.00 million in outstanding shares. This repurchase authorization allows the biotechnology company to buy up to 9.6% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

ANAB has been the topic of several recent analyst reports. HC Wainwright cut their price target on AnaptysBio from $52.00 to $51.00 and set a “buy” rating on the stock in a research note on Monday, November 24th. Guggenheim reiterated a “buy” rating on shares of AnaptysBio in a research note on Thursday, December 18th. Wells Fargo & Company upped their target price on shares of AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Barclays reduced their target price on AnaptysBio from $70.00 to $55.00 and set an “overweight” rating on the stock in a report on Wednesday, December 17th. Finally, Wall Street Zen upgraded AnaptysBio from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 16th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $55.40.

Read Our Latest Analysis on AnaptysBio

AnaptysBio Profile

(Free Report)

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.

Featured Articles

Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio, Inc. (NASDAQ:ANAB – Free Report).